Search for: "Teva Branded Pharmaceutical Products R"
Results 1 - 20
of 96
Sort by Relevance
|
Sort by Date
3 Apr 2024, 1:07 pm
The Federal Trade Commission (“FTC”) has filed an amicus brief in Teva Branded Pharmaceuticals Products R&D, Inc. v. [read post]
26 Mar 2024, 7:01 pm
Late last week, the FTC submitted an Amicus Brief in recent Hatch-Waxman patent litigation in the District Court of New Jersey between Reference Listed Drug holder Teva Branded Pharmaceutical Products R&D Inc. and ANDA applicant Amneal Pharmaceuticals explaining that patents that claim the device constituent of a combination product but do not expressly claim the relevant drug substance should not be listed in the Orange Book.… [read post]
5 Dec 2022, 6:55 am
In Teva Branded Pharmaceutical Products R&D, Inc. v. [read post]
5 Dec 2022, 6:55 am
In Teva Branded Pharmaceutical Products R&D, Inc. v. [read post]
5 Dec 2022, 6:55 am
In Teva Branded Pharmaceutical Products R&D, Inc. v. [read post]
1 Dec 2021, 6:22 am
The main defendants at issue in the Elmiron litigation include Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson Pharmaceuticals, Inc.), Teva Branded Pharmaceutical Products R&D, Inc., and Teva Pharmaceuticals USA, Inc. [read post]
1 Dec 2021, 6:22 am
The main defendants at issue in the Elmiron litigation include Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson Pharmaceuticals, Inc.), Teva Branded Pharmaceutical Products R&D, Inc., and Teva Pharmaceuticals USA, Inc. [read post]
1 Dec 2021, 6:22 am
The main defendants at issue in the Elmiron litigation include Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson Pharmaceuticals, Inc.), Teva Branded Pharmaceutical Products R&D, Inc., and Teva Pharmaceuticals USA, Inc. [read post]
24 Aug 2021, 2:10 am
The Hatch-Waxman Act allows the FDA to permit a generic version of a branded product, which is partially patent protected, to come to market if the generic manufacturer “carves out” the patent-protected indication from its label. [read post]
26 Oct 2020, 2:49 am
The summary of product characteristics provides for a mandatory premedication regime under which the drug must be combined with vitamin B 12, as also stated in patent EP 508. [read post]
8 May 2020, 6:57 pm
Eagle suedSlayback Pharma LLC for infringing four patents coveringEagle’s brand name bendamustine pharmaceutical product. [read post]
22 Nov 2019, 6:59 am
It means that companies are often paid many times above the costs of production and should be incentivised to undertake further innovation. [read post]
15 May 2019, 5:27 am
Kluwer Patent blogger44 U.S. states filed a lawsuit last Friday accusing Teva Pharmaceuticals USA of conspiring illegally with 19 other drug companies to inflate drug prices – sometimes by more than 1,000 percent – and stifle competition for generic drugs. [read post]
28 Dec 2017, 2:44 am
How to right the ship with respect to its generic products, while also ramping up the necessary R&D to support a viable proprietary drug business, is daunting for even the largest pharmaceutical company. [read post]
8 Feb 2017, 3:09 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
16 Jan 2017, 5:44 pm
Teva Pharmaceuticals USA, Inc., et al. [read post]
14 Nov 2016, 9:16 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
28 Sep 2016, 8:39 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
16 Jun 2015, 6:00 am
Teva Pharmaceutical Industries, Ltd. will make a total of $1.2B available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon’s illegal conduct. [read post]
19 Mar 2015, 12:41 pm
Some generic drug makers and insurers want biosimilars to have the same generic name as the branded product, because that would make it easier for doctors to use them as substitutes. [read post]
